Last reviewed · How we verify
NCT06288334
Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children
Phase 4 trial testing 1-3 Cetirizine Pharmacokinetic samples in Allergic Disease in 80 participants. Status unknown.
31 March 2024
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 6 August 2020 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 1-3 Cetirizine Pharmacokinetic samples
Conditions studied
- Allergic Disease — all drugs for Allergic Disease →
- Children — all drugs for Children →
Sponsor
Peking University Third Hospital
Who can join
Adults 6 Months to 16, any sex, with Allergic Disease or Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To obtain the pharmacokinetics of cetirizine in Chinese children with allergic disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06288334
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Disease
Currently open trials in the same condition.
- NCT07356713 — A Study to Find a Suitable Dose of Exl-111 for Further Research · Phase 1 · recruiting
- NCT07316465 — Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis · NA · recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06288334 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06288334.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing